论文部分内容阅读
24例子宫内膜异位症患者,年龄26～41岁,由腹腔镜检查或开腹探查确诊.于滤泡早期开始皮下注射促黄体生成激素释放激素类似物(LHRH—A),每次200μg,每日两次,连续应用24～34周.用药6个月时行子宫內膜活检,部分在用药中期也取了活检。病理类型10例为静止型,3例呈增殖型,4例未获得足够的标本送病检,血清E_2都压抑在低于滤泡早期或接近绝经期水平,伴随闭经.有6例內膜呈单纯型或腺囊型增生过长,1例呈分泌型,其血清E_2水平具有明显波动,并伴有阴道出血.长期连续应用LHRH—A能可靠地抑制排卵,压抑血清E_2水平,使內膜組织萎缩.
Twenty-four patients with endometriosis, ages 26-41, were diagnosed by laparoscopy or open laparotomy, and luteinizing hormone releasing hormone analogues (LHRH-A) , Twice a day, continuous application of 24 to 34 weeks .6 months when the endometrial biopsy, some in the middle of medication also took biopsy. Pathological type of 10 cases were quiescent type, 3 cases were proliferative, 4 cases did not get enough specimens sent to the pathological examination, serum E_2 were suppressed below the follicular early or near the menopause level, accompanied by amenorrhea.6 cases of endometrial Simple or glandular cyst hyperplasia, 1 cases were secreted, the serum E_2 levels fluctuate significantly, accompanied by vaginal bleeding. Long-term continuous application of LHRH-A can reliably inhibit ovulation, suppress serum E_2 levels, the intima Tissue atrophy.